Clinical Trials
8 trialsNCT04729387 2026-06-04
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT05252390 2025-11-06
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT06065059 2024-08-13
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT03924245 2022-04-04
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated